Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab.

Antibodies, Bispecific / therapeutic use Antineoplastic Agents / therapeutic use Australia Child Female Humans Male Neoplasm Recurrence, Local / drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy Retrospective Studies Treatment Outcome
acute lymphoblastic leukaemia blinatumomab paediatric refractory relapse

Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
05 2021
Historique:
revised: 22 12 2020
received: 18 11 2020
accepted: 10 01 2021
pubmed: 28 2 2021
medline: 15 10 2021
entrez: 27 2 2021
Statut: ppublish

Résumé

We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.

Identifiants

DOI: 10.1002/pbc.28922 PMID: 33638292
pubmed: 33638292
doi: 10.1002/pbc.28922
doi:

Substances chimiques

Antibodies, Bispecific 0
Antineoplastic Agents 0
blinatumomab 4FR53SIF3A

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28922

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Phelan KW, Advani AS. Novel therapies in acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2018;13(4):289-299.
Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
Rheingold SR, Ji L, Xu X, et al. Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children's Oncology Group (COG) study. J Clin Oncol. 2019;37(15_suppl):10008.
Sun W, Malvar J, Sposto R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32(11):2316-2325.
von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381-4389.
Locatelli F, Whitlock JA, Peters C, et al. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020;34(9):2473-2478.
Brown PA, Ji L, Xu X, et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk first relapse of B-acute lymphoblastic leukemia in children and adolescents/young adults demonstrates superior efficacy and tolerability of blinatumomab: a report from the Children's Oncology Group study AALL1331. Blood. 2019;134(Supplement_2):LBA-1.
Keating AK, Gossai N, Phillips CL, et al. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv. 2019;3(13):1926-1929.
Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(1):e28718.
Clesham K, Rao V, Bartram J, et al. Blinatumomab for infant acute lymphoblastic leukemia. Blood. 2020;135(17):1501-1504.
Mouttet B, Vinti L, Ancliff P, et al. Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica. 2019;104(6):e244-e247.
Meyer C, Burmeister T, Groger D, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32(2):273-284.
Heatley SL, Sadras T, Kok CH, et al. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica. 2017;102(12):e490-e493.
van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-611.
Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008;22(12):2142-2150.
Irving JA, Enshaei A, Parker CA, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128(7):911-922.
Parker C, Krishnan S, Hamadeh L, et al. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematol. 2019;6(4):e204-e216.
Bhatla T, Hogan L, Xu X, et al. Cytogenetic subgroups drive risk stratification and response to chemotherapy and blinatumomab in children and young adults with relapsed B-ALL: a Children's Oncology Group study. Blood. 2020;136(Supplement 1):16-17.

Auteurs

Rosemary Sutton (R)

Molecular Diagnostics, Children's Cancer Institute, Sydney, New South Wales, Australia.
School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia.

Luciano Dalla Pozza (LD)

Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.

Seong Lin Khaw (SL)

Children's Cancer Centre, The Royal Children's Hospital, Melbourne, Victoria, Australia.

Chris Fraser (C)

Blood and Bone Marrow Transplant Program, Queensland Children's Hospital, Brisbane, Queensland, Australia.

Tom Revesz (T)

Department of Clinical Haematology and Oncology, Women's and Children's Hospital, Adelaide, South Australia, Australia.
University of Adelaide, Adelaide, South Australia, Australia.

Janis Chamberlain (J)

John Hunter Children's Hospital, Newcastle, New South Wales, Australia.

Richard Mitchell (R)

School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia.
Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.

Toby N Trahair (TN)

Molecular Diagnostics, Children's Cancer Institute, Sydney, New South Wales, Australia.
School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia.
Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.
ORCID: 0000-0002-3295-228X

Caroline M Bateman (CM)

Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.

Nicola C Venn (NC)

Molecular Diagnostics, Children's Cancer Institute, Sydney, New South Wales, Australia.

Tamara Law (T)

Molecular Diagnostics, Children's Cancer Institute, Sydney, New South Wales, Australia.

Erika Ong (E)

Molecular Diagnostics, Children's Cancer Institute, Sydney, New South Wales, Australia.

Susan L Heatley (SL)

University of Adelaide, Adelaide, South Australia, Australia.
Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

Barbara J McClure (BJ)

University of Adelaide, Adelaide, South Australia, Australia.
Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

Claus Meyer (C)

Institute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe University, Frankfurt, Germany.

Rolf Marschalek (R)

Institute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe University, Frankfurt, Germany.

Michelle J Henderson (MJ)

Molecular Diagnostics, Children's Cancer Institute, Sydney, New South Wales, Australia.
School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia.

Siobhan Cross (S)

Children's Haematology/Oncology Centre, Christchurch Hospital, Christchurch, New Zealand.

Deborah L White (DL)

University of Adelaide, Adelaide, South Australia, Australia.
Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Australian Genomics Health Alliance, Parkville, Melbourne, Victoria, Australia.

Rishi S Kotecha (RS)

Department of Clinical Haematology, Oncology and Bone Marrow Transplantation, Perth Children's Hospital, Perth, Western Australia, Australia.
Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Western Australia, Australia.
ORCID: 0000-0003-1836-4075

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bispécifiques › Outcomes for Australian children with...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Outcomes for Australian children with...
questionsmedicales.fr › Régions géographiques › Océanie › Australasie › Australie › Outcomes for Australian children with...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Outcomes for Australian children with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Outcomes for Australian children with...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Outcomes for Australian children with...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › Outcomes for Australian children with...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Outcomes for Australian children with...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Outcomes for Australian children with...